AssetMark Inc
ITCI

AssetMark Inc’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

AssetMark Inc’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-281
Closed -$37.1K – 3150
2025
Q1 		$37.1K Sell
281
-2,003
-88% -$250K ﹤0.01% 1517
2024
Q4 		$191K Sell
2,284
-193
-8% -$15.9K ﹤0.01% 1107
2024
Q3 		$181K Buy
2,477
+207
+9% +$15.6K ﹤0.01% 1034
2024
Q2 		$155K Buy
2,270
+243
+12% +$16.9K ﹤0.01% 1038
2024
Q1 		$140K Sell
2,027
-209
-9% -$14.4K ﹤0.01% 1005
2023
Q4 		$160K Buy
2,236
+338
+18% +$19.4K ﹤0.01% 958
2023
Q3 		$98.9K Buy
1,898
+103
+6% +$6K ﹤0.01% 985
2023
Q2 		$114K Buy
1,795
+1,035
+136% +$64.5K ﹤0.01% 923
2023
Q1 		$41.2K Buy
760
+125
+20% +$6.04K ﹤0.01% 1077
2022
Q4 		$33.6K Hold
635
– – ﹤0.01% 1123
2022
Q3 		$30K Buy
635
+125
+25% +$6.53K ﹤0.01% 1055
2022
Q2 		$29K Buy
510
+410
+410% +$23.2K ﹤0.01% 1051
2022
Q1 		$6K Buy
100
+40
+67% +$2.08K ﹤0.01% 1259
2021
Q4 		$3K Buy
+60
New +$2.52K ﹤0.01% 1336

Other funds holding ITCI

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
KIM
Kestra Investment Management Austin, Texas $5.8B AUM 14.71% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

AssetMark Inc's ITCI Position: Q2 2025 in Review

AssetMark Inc sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 281 shares — an estimated $37.1K sold.

AssetMark Inc first reported a position in ITCI in Q4 2021 and held it in 14 quarters. The position peaked at $191K in Q4 2024. 4 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

  • AssetMark Inc reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
  • AssetMark Inc sold 281 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $37.1K.
  • AssetMark Inc first reported a position in Intra-Cellular Therapies Inc. in Q4 2021 and held it in 14 quarters.
  • AssetMark Inc's Intra-Cellular Therapies Inc. position peaked at $191K in Q4 2024.
  • 4 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on AssetMark Inc's 13F filing for Q2 2025, filed 4 Aug 2025.